The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Human Microbiome Therapeutics Market Research Report 2024
Synopsis
Human microbiome has co-evolved with humans for centuries, which includes bacteria, viruses, fungi, Achaeans etc. The human microbiome is now one of the fastest growing areas of biology, and is considered as a newly discovered organ with the potential to have a tremendous impact on human health. Microbiome therapeutics are therapies that are designed to disrupt unhealthy microbial ecological networks and that catalyse the establishment of healthy ones.
The global Human Microbiome Therapeutics market was valued at US$ 965.7 million in 2023 and is anticipated to reach US$ 1590.9 million by 2030, witnessing a CAGR of 7.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Human Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Microbiome Therapeutics.
Report Scope
The Human Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Microbiome Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Enterome Bioscience
Rebiotix
Seres Therapeutics
Vedanta Biosciences
Bristol-Myers Squibb
Johnson & Johnson
Takeda Pharmaceutical
Segment by Type
FMT
Microbiome Drugs
Segment by Application
C. difficile
Crohn’s Disease
Inflammatory Bowel Disease
Diabetes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Microbiome Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Human microbiome has co-evolved with humans for centuries, which includes bacteria, viruses, fungi, Achaeans etc. The human microbiome is now one of the fastest growing areas of biology, and is considered as a newly discovered organ with the potential to have a tremendous impact on human health. Microbiome therapeutics are therapies that are designed to disrupt unhealthy microbial ecological networks and that catalyse the establishment of healthy ones.
The global Human Microbiome Therapeutics market was valued at US$ 965.7 million in 2023 and is anticipated to reach US$ 1590.9 million by 2030, witnessing a CAGR of 7.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Human Microbiome Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Microbiome Therapeutics.
Report Scope
The Human Microbiome Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Microbiome Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Microbiome Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Enterome Bioscience
Rebiotix
Seres Therapeutics
Vedanta Biosciences
Bristol-Myers Squibb
Johnson & Johnson
Takeda Pharmaceutical
Segment by Type
FMT
Microbiome Drugs
Segment by Application
C. difficile
Crohn’s Disease
Inflammatory Bowel Disease
Diabetes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human Microbiome Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Human Microbiome Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 FMT
1.2.3 Microbiome Drugs
1.3 Market by Application
1.3.1 Global Human Microbiome Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 C. difficile
1.3.3 Crohn’s Disease
1.3.4 Inflammatory Bowel Disease
1.3.5 Diabetes
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Human Microbiome Therapeutics Market Perspective (2019-2030)
2.2 Human Microbiome Therapeutics Growth Trends by Region
2.2.1 Global Human Microbiome Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Human Microbiome Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Human Microbiome Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Human Microbiome Therapeutics Market Dynamics
2.3.1 Human Microbiome Therapeutics Industry Trends
2.3.2 Human Microbiome Therapeutics Market Drivers
2.3.3 Human Microbiome Therapeutics Market Challenges
2.3.4 Human Microbiome Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Human Microbiome Therapeutics Players by Revenue
3.1.1 Global Top Human Microbiome Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Human Microbiome Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Human Microbiome Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Human Microbiome Therapeutics Revenue
3.4 Global Human Microbiome Therapeutics Market Concentration Ratio
3.4.1 Global Human Microbiome Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human Microbiome Therapeutics Revenue in 2023
3.5 Human Microbiome Therapeutics Key Players Head office and Area Served
3.6 Key Players Human Microbiome Therapeutics Product Solution and Service
3.7 Date of Enter into Human Microbiome Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Human Microbiome Therapeutics Breakdown Data by Type
4.1 Global Human Microbiome Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Human Microbiome Therapeutics Forecasted Market Size by Type (2025-2030)
5 Human Microbiome Therapeutics Breakdown Data by Application
5.1 Global Human Microbiome Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Human Microbiome Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Human Microbiome Therapeutics Market Size (2019-2030)
6.2 North America Human Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Human Microbiome Therapeutics Market Size by Country (2019-2024)
6.4 North America Human Microbiome Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Human Microbiome Therapeutics Market Size (2019-2030)
7.2 Europe Human Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Human Microbiome Therapeutics Market Size by Country (2019-2024)
7.4 Europe Human Microbiome Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Human Microbiome Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Human Microbiome Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Human Microbiome Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Human Microbiome Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Human Microbiome Therapeutics Market Size (2019-2030)
9.2 Latin America Human Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Human Microbiome Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Human Microbiome Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Human Microbiome Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Human Microbiome Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Human Microbiome Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Human Microbiome Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Enterome Bioscience
11.1.1 Enterome Bioscience Company Detail
11.1.2 Enterome Bioscience Business Overview
11.1.3 Enterome Bioscience Human Microbiome Therapeutics Introduction
11.1.4 Enterome Bioscience Revenue in Human Microbiome Therapeutics Business (2019-2024)
11.1.5 Enterome Bioscience Recent Development
11.2 Rebiotix
11.2.1 Rebiotix Company Detail
11.2.2 Rebiotix Business Overview
11.2.3 Rebiotix Human Microbiome Therapeutics Introduction
11.2.4 Rebiotix Revenue in Human Microbiome Therapeutics Business (2019-2024)
11.2.5 Rebiotix Recent Development
11.3 Seres Therapeutics
11.3.1 Seres Therapeutics Company Detail
11.3.2 Seres Therapeutics Business Overview
11.3.3 Seres Therapeutics Human Microbiome Therapeutics Introduction
11.3.4 Seres Therapeutics Revenue in Human Microbiome Therapeutics Business (2019-2024)
11.3.5 Seres Therapeutics Recent Development
11.4 Vedanta Biosciences
11.4.1 Vedanta Biosciences Company Detail
11.4.2 Vedanta Biosciences Business Overview
11.4.3 Vedanta Biosciences Human Microbiome Therapeutics Introduction
11.4.4 Vedanta Biosciences Revenue in Human Microbiome Therapeutics Business (2019-2024)
11.4.5 Vedanta Biosciences Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Detail
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Human Microbiome Therapeutics Introduction
11.5.4 Bristol-Myers Squibb Revenue in Human Microbiome Therapeutics Business (2019-2024)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Detail
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Human Microbiome Therapeutics Introduction
11.6.4 Johnson & Johnson Revenue in Human Microbiome Therapeutics Business (2019-2024)
11.6.5 Johnson & Johnson Recent Development
11.7 Takeda Pharmaceutical
11.7.1 Takeda Pharmaceutical Company Detail
11.7.2 Takeda Pharmaceutical Business Overview
11.7.3 Takeda Pharmaceutical Human Microbiome Therapeutics Introduction
11.7.4 Takeda Pharmaceutical Revenue in Human Microbiome Therapeutics Business (2019-2024)
11.7.5 Takeda Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
